Cargando…
Echocardiographic analysis of acute effects of percutaneous mitral annuloplasty on severity of secondary mitral regurgitation
AIMS: Percutaneous mitral annuloplasty (PMA) represents a new treatment option for secondary mitral regurgitation (SMR) being associated with higher morbidity and mortality. The present study was aimed to evaluate whether or not acute effects on SMR severity can quantitatively be assessed after PMA....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373905/ https://www.ncbi.nlm.nih.gov/pubmed/32358886 http://dx.doi.org/10.1002/ehf2.12719 |
Sumario: | AIMS: Percutaneous mitral annuloplasty (PMA) represents a new treatment option for secondary mitral regurgitation (SMR) being associated with higher morbidity and mortality. The present study was aimed to evaluate whether or not acute effects on SMR severity can quantitatively be assessed after PMA. METHODS AND RESULTS: PMA was performed in 30 patients (mean age 76 ± 9; 37% males) with moderate (n = 14) or severe (n = 16) SMR. Vena contracta (VC), left ventricular (LV) velocity‐time‐integral ratio (VTI(MV/LVOT)), effective regurgitant orifice area (EROA) by two‐dimensional proximal isovelocity surface area (PISA), regurgitant volume (RVol(PISA)) and regurgitant fraction (RF(PISA)) by PISA, RVol(volume) and RF(volume) by LV volume analyses, and parameters describing LV morphology, function, and cardiac performance were assessed by transthoracic echocardiography prior to and after PMA. According to RF(PISA)/RF(volume), 14 patients showed mild, 15 moderate, and 1 severe SMR after PMA. Mean RF, RVol, EROA, VC, and VTI(MV/LVOT) were lower directly after PMA (RF(PISA): 49% ± 11 vs. 34% ± 13, P < 0.001; RF(volume): 46% ± 10 vs. 34% ± 13, P < 0.001; RVol(PISA): 33 mL ± 13 vs. 25 mL ± 12, P < 0.001; RVol(volume): 28 mL ± 17 vs. 20 mL ± 14, P < 0.05; EROA(PISA): 0.24 cm(2) ± 0.1 vs. 0.19 cm(2) ± 0.1, P < 0.05; VC: 5.2 ± 0.1 vs. 4.1 ± 0.2, P < 0.001; VTI(MV/LVOT): 1.9 ± 0.4 vs. 1.6 ± 0.5, P < 0.05). Parameters of LV morphology, function, and cardiac performance did not change directly after PMA. CONCLUSIONS: PMA leads to a reduction of MR severity in >80% of SMR patients. Acute effects of PMA can quantitatively be assessed by transthoracic echocardiography. |
---|